Division of Endocrinology, Department of Internal Medicine, Amsterdam University Medical Center, Amsterdam, The Netherlands.
Northwest Clinics, Department of Endocrinology, Alkmaar, The Netherlands.
Eur J Endocrinol. 2020 Nov;183(5):529-536. doi: 10.1530/EJE-20-0609.
Transgender individuals sometimes report a lack of physical change during hormone treatment, such as alterations in muscle tone or fat distribution. Identifying characteristics of this subgroup could be a step toward individualizing hormone therapy in transgender individuals. Therefore, we study the variation of changes in body composition and characteristics associated with a lack of change.
Body composition measures were recorded in 323 transmen and 288 transwomen at every visit from the start of hormone therapy to a maximum of 24 months follow-up. Absence of change was defined as transmen with a decrease in lean body mass or transwomen with a decrease in fat percentage.
A lack of change at 24 months was observed in 19 of 94 (20.2%) transmen and in 9 of 96 (9.4%) transwomen. The risk of not achieving change in body composition was related to lower testosterone levels and less suppression of LH in transmen (OR: 0.67, 95% CI: 0.48-0.94 per SD increase in testosterone and OR: 1.36, 95% CI: 1.01-1.83 per SD increase in LH).
There is a large variation in body composition changes during hormone therapy, with a substantial proportion of individuals with no measurable effects. In transmen, serum testosterone and LH were associated with a lack of change, but serum hormone levels were not associated with body composition changes in transwomen. The results provide a rationale for individualizing hormone therapy in transmen, by considering individual effects rather than solely relying on a standardized dosage of hormone therapy.
跨性别者在接受激素治疗时有时会报告身体变化不明显,例如肌肉张力或脂肪分布的改变。确定这一小部分人群的特征可能是实现跨性别者个体化激素治疗的一步。因此,我们研究了身体成分变化的变异性以及与变化不明显相关的特征。
从激素治疗开始到最长 24 个月的随访期间,对 323 名跨男性和 288 名跨女性的身体成分测量值进行了记录。没有变化的定义是指跨男性的瘦体重减少或跨女性的脂肪百分比减少。
在 94 名跨男性中的 19 名(20.2%)和 96 名跨女性中的 9 名(9.4%)在 24 个月时观察到没有变化。未能实现身体成分变化的风险与较低的睾丸激素水平和较低的 LH 抑制有关在跨男性中(OR:0.67,95%CI:每 SD 增加睾丸激素增加 0.48-0.94,OR:1.36,95%CI:每 SD 增加 LH 增加 1.01-1.83)。
在激素治疗期间,身体成分的变化存在很大差异,很大一部分个体没有可测量的效果。在跨男性中,血清睾丸激素和 LH 与没有变化有关,但血清激素水平与跨女性的身体成分变化无关。这些结果为跨男性的个体化激素治疗提供了依据,考虑个体效应而不仅仅依赖于标准化的激素治疗剂量。